Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Central Chorioretinitis (COAST_UAcCNV)

Collaborative Ocular Antiangiogenic Study of Ukraine. Multicentral, Open-label, Randomized, Prospective Study of Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Central Chorioretinitis

The purpose of this study is to determine the effectiveness of antiangiogenic therapy to choroidal neovascularization secondary to central chorioretinitis.

Study Overview

• Status: Unknown
• Conditions: Chorioretinitis
• Intervention / Treatment: Diagnostic test: Visometry; Diagnostic test: Fluorescent angiography; Diagnostic test: Refractometry; Diagnostic test: Slit lamp examination; Diagnostic test: Ophthalmoscopy; Diagnostic test: OKT; Procedure: Intravitreal injection

Detailed Description

The purpose of this study is to determine the effectiveness of antiangiogenic therapy to choroidal neovascularization secondary to central chorioretinitis.

This study is planned as a follow-up. Patients with central chorioretinitis included in it will receive antiangiogenic therapy in accordance with the approved indications for use indicated in the instructions for the use of drugs in Ukraine.

The treatment proposed in this study is based on the world experience and scientific developments of the Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine ". Therefore, it is expected that the benefit / risk ratio in relation to the participation in this study should not be different from that described in the scientific literature and the benefits outweigh the risk. It is known that the absence of treatment in these diseases leads to an irreparable loss of central vision.

• Study Type: Interventional
• Enrollment (Anticipated): 100
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Ukraine
  • Mykolaiv, Ukraine, 54000
    • Recruiting
    • Mykolaiv Region Ophthalmogical Hospital
  • Odessa, Ukraine, 65028
    • Recruiting
    • Odessa National Medical University
  • Odessa, Ukraine, 65061
    • Recruiting
    • The Filatov Institute of Eye Diseases and Tissue Therapy

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 90 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Able to read (or, if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent form or a family member) and understand the informed consent form and willing to sign the informed consent form.
• Signed informed consent form.
• Men and women ≥ 18 years of age.
• Willing, committed, and able to return for all clinic visits and complete all study-related procedures.
• First diagnosed active subfoveal or juxtafoveal (within 1 to 199 μm of the center of the fovea) CNV secondary to chorioretinitis as defined by leakage on FA
• Transparent optical media and possibility to mydriasis.
• Best corrected visual acuity at least 20/100 Equivalent of Snellen (ETDRS).

Exclusion Criteria:

• Ocular media of insufficient quality to obtain fundus and OCT images in the study eye
• Recurrent CNV in the study eye
• History or presence of CNV with an origin other than chorioretinitis in the study eye
• Ocular inflammation or external ocular inflammation in the study eye
• Concurrent disease in the study eye that would compromise BCVA or require medical or surgical intervention during the study period
• Any ocular disorder in the study eye that, in the opinion of the investigator, may confound interpretation of the study results
• Significant scarring or atrophy in the fovea that indicates substantial irreversible vision loss in the study eye
• Evidence at examination of infectious blepharitis, keratitis, scleritis, or conjunctivitis in either eye or current treatment for serious systemic infection
• Vitreomacular traction or traction retinal detachment, epiretinal membrane in either eye
• Any iris neovascularization and/or vitreous hemorrhage in either eye
• Uncontrolled glaucoma, or previous filtration surgery in either eye
• Maсular hole.
• Any prior or concomitant treatment with another investigational agent for CNV in the study eye.
• Any previous panretinal photocoagulation or subfoveal thermal laser therapy in the study eye.
• Any prior treatment with photodynamic therapy in the study eye.
• Cataract surgery within 3 months prior to Day 1 in the study eye.
• Yttrium-aluminum-garnet laser capsulotomy within 2 months prior to Day 1 in the study eye.
• Any other intraocular surgery within 3 months prior to Day 1 in the study eye.
• History of vitreoretinal surgery and/or scleral buckle surgery in the study eye.
• Any prior treatment with anti-VEGF agents
• Previous use of intraocular or periocular corticosteroids in either eye within 3 months prior to Day 1
• Previous assignment to treatment during this study
• Uncontrolled hypertension
• History of cerebrovascular disease or myocardial infarction within 6 months prior to Baseline/Day 1
• History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect interpretation of the results of the study, or renders the subject at high risk from treatment complications
• Women of childbearing potential without contraception, women who intend to breastfeed during the study. All subjects (both men and women) of childbearing potential who are unwilling to use adequate birth control measures during the course of the study.
• Renal failure requiring dialysis or renal transplant
• Participation in an investigational study within 30 days prior to Screening/Visit 1 that involved treatment with any drug (excluding vitamins and minerals) or device
• Known serious allergy to the fluorescein sodium for injection in angiography or Verteporfin
• Inability to obtain fundus photographs or fluorescein angiograms of sufficient quality

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: Ranibizumab; Arm 1	Diagnostic test: Visometry; Ophthalmic examination; Diagnostic test: Fluorescent angiography; Ophthalmic examination; Diagnostic test: Refractometry; Ophthalmic examination; Diagnostic test: Slit lamp examination; Ophthalmic examination; Diagnostic test: Ophthalmoscopy; Ophthalmic examination; Diagnostic test: OKT; Ophthalmic examination; Procedure: Intravitreal injection; Intravitreal injection of Aflibercept 2 mg (0.05 ml) or Ranibizumab 0.5 mg (0.05 ml) to the regimen pro re nata.; Other Names: Patients after general ophthalmic examination receive an injection according to the regimen pro re nata.
ACTIVE_COMPARATOR: Aflibercept; Arm 2	Diagnostic test: Visometry; Ophthalmic examination; Diagnostic test: Fluorescent angiography; Ophthalmic examination; Diagnostic test: Refractometry; Ophthalmic examination; Diagnostic test: Slit lamp examination; Ophthalmic examination; Diagnostic test: Ophthalmoscopy; Ophthalmic examination; Diagnostic test: OKT; Ophthalmic examination; Procedure: Intravitreal injection; Intravitreal injection of Aflibercept 2 mg (0.05 ml) or Ranibizumab 0.5 mg (0.05 ml) to the regimen pro re nata.; Other Names: Patients after general ophthalmic examination receive an injection according to the regimen pro re nata.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Chart	Defined study baseline range of ETDRS equivalent of 20/200 to 20/20) in the study eye; a higher score represents better functioning.	Baseline-Month 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Change in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT)	A negative number indicates improvement (reduced thickness).	Baseline-Month 12
Average Number of Intravitreal Injections	The number of intravitreal injections administered	Baseline-Month 12
Number of Endophthalmitis after Intravitreal Injections	The number of endophthalmitis registered in patients after intravitreal injections	Baseline-Month 12

Collaborators and Investigators

• Sponsor: The Filatov Institute of Eye Diseases and Tissue Therapy
• Collaborators: Odessa National Medical University; Mykolaiv Region Ophthalmogical Hospital; Central Polyclinic of Internal Affairs of Ukraine

Study record dates

Study Major Dates

• Study Start (ACTUAL): March 27, 2018
• Primary Completion (ANTICIPATED): December 31, 2021
• Study Completion (ANTICIPATED): January 31, 2022

Study Registration Dates

• First Submitted: November 29, 2019
• First Submitted That Met QC Criteria: January 27, 2020
• First Posted (ACTUAL): January 28, 2020

Study Record Updates

• Last Update Posted (ACTUAL): February 3, 2021
• Last Update Submitted That Met QC Criteria: February 2, 2021
• Last Verified: February 1, 2021

More Information

Terms related to this study

• Keywords: intravitreal injection; anti-VEGF; choroidal neovascularization; antiangiogenic therapy; fundus diseases; central chorioretinitis
• Additional Relevant MeSH Terms: Pathologic Processes; Eye Diseases; Retinal Diseases; Panuveitis; Uveitis; Uveal Diseases; Choroid Diseases; Metaplasia; Choroiditis; Retinitis; Uveitis, Posterior; Choroidal Neovascularization; Neovascularization, Pathologic; Chorioretinitis
• Other Study ID Numbers: 0118U001612/2

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No